A daily pill is offering people with obesity and Type 2 diabetes a simpler path to meaningful weight loss and better blood sugar control. In a large international trial, an oral GLP-1 medication called orforglipron delivered clinically significant benefits without the needles, refrigeration, or complexity that accompany today’s injectable drugs.
The ATTAIN-2 trial, a 72-week phase 3 study published in The Lancet and led by UTHealth Houston, tested orforglipron, a once-daily small-molecule GLP-1 receptor agonist, in 1,613 adults across 136 sites in ten countries. Participants all had obesity and Type 2 diabetes. They received escalating doses of the pill, alongside lifestyle guidance that emphasized portion control, regular meals, protein and fiber intake, and 150 minutes of weekly physical activity. The core finding was clear: orforglipron reduced body weight by 5 to nearly 10 percent depending on dose, improved blood sugar, and produced only mild to moderate gastrointestinal side effects.
What sets orforglipron apart is its form. Unlike current GLP-1 treatments that require injections, refrigeration, and come with needle-related discomfort, this medication is a true pill: no cold chain, no timing restrictions around food or water, and no syringes. Researchers say that convenience could broaden access for millions who struggle with or avoid injectable therapies.
“The Opportunity For An Oral GLP-1 Medication”
“The opportunity for an oral GLP-1 medication with highly effective weight loss that is simpler to take may provide increased access and opportunities for better health for our patients with obesity and diabetes,” said Deborah Horn, DO, MPH, professor and director of obesity medicine at McGovern Medical School at UTHealth Houston and principal author of the study.
Orforglipron is designed to stimulate insulin, suppress glucagon, and reduce appetite, mirroring the biological effects of injectable GLP-1 drugs but in tablet form. Earlier trials in adults with obesity but without diabetes showed over 12 percent weight loss at 72 weeks. ATTAIN-2 extends those findings into a harder-to-treat population, since people with diabetes tend to lose less weight on the same medications. Despite that challenge, the highest dose group in ATTAIN-2 lost an average of 10.5 percent of their body weight, compared to 2.2 percent in the placebo group.
Importantly, the study used a lifestyle approach different from strict calorie-restriction protocols typical of obesity trials. Instead of mandating a 500-calorie deficit, participants were coached on sustainable behaviors like meal regularity and balanced nutrient intake. The pill’s benefits emerged on top of these real-world recommendations.
“It Is Exciting To Have An Oral Medication”
“We know it is harder for individuals with diabetes to lose weight. It is exciting to have an oral medication that provides double-digit weight loss, which on average was 23 lbs. Once FDA approved, orforglipron is scheduled to be available in 2026 at a significantly decreased cost compared to current injectables. This could position it to be the ‘metformin’ of obesity and become widely covered by insurance plans, opening the door to treatment for all,” Horn said.
Across all doses, orforglipron improved blood sugar measures including HbA1c, aligning with its mechanism and matching the metabolic benefits seen in injectable GLP-1 therapies. Adverse events were primarily gastrointestinal and occurred mostly during dose escalation. Study investigators deemed the small number of deaths in the trial unrelated to treatment, with one exception in the intermediate dose group that was not attributed to the drug.
If approved, orforglipron could become the first widely available oral GLP-1 therapy for both weight loss and diabetes management. Its ease of use, lower anticipated cost, and familiar pill format could reshape the treatment landscape, potentially bringing powerful metabolic tools to populations that have been unable or unwilling to use injections. For patients and clinicians, that shift could mark a long-awaited expansion of access in obesity and diabetes care.
The Lancet: 10.1016/S0140-6736(25)02165-8
ScienceBlog.com has no paywalls, no sponsored content, and no agenda beyond getting the science right. Every story here is written to inform, not to impress an advertiser or push a point of view.
Good science journalism takes time — reading the papers, checking the claims, finding researchers who can put findings in context. We do that work because we think it matters.
If you find this site useful, consider supporting it with a donation. Even a few dollars a month helps keep the coverage independent and free for everyone.